Summary
This report summarizes studies of the toxicology of two antitumor drugs, l-phenylalanine mustard (l-PAM) and 5-fluorouracil (5-FU), administered singly and in combination to tumor-free and tumor-bearing mice. The purpose was to obtain data that might reveal the effect of disease on standard endpoints of drug toxicity. Young adult female B6C3F1 mice free of tumor or bearing murine mammary adenocarcinoma 16/C were treated with various dosages or combinations of l-PAM and 5-FU. All experiments included diluent control groups, and treatments were all administered IP daily for 5 days. Tumor size, body weight, hematology, clinical chemistry, and histopathology data were obtained on days 19, 21, 24, 28, 32, and 39 (day of tumor implantation = day 1; treatment on days 14–18), or on the corresponding post-treatment days in tumor-free mice. Tumor-bearing mice exhibited notable abnormalities in peripheral hematologic values and in concentrations of plasma urea nitrogen. If no drug treatment was administered, persistent reticulocytosis, granulocytosis, and uremia occurred in these mice. These abnormalities seemed to be related to tumor growth; drug treatment that produced partial regressions temporarily moderated cell counts and urea nitrogen concentrations. In general, these effects were observed in tumor-bearing mice receiving the highest doses in each experiment, suggesting that tumor-bearing mice are less sensitive than tumor-free mice to the effects of drugs on vital normal cells. Our data suggest that in the case of the particular tumor, host strain, and drugs studied here, distinct qualitative and quantitative differences in toxicity are obserbed when responses of tumor-free and tumor-bearing mice are compared.
Similar content being viewed by others
References
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405
Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904
Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1978) Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471
Denine EP, Harrison SD Jr, Peckham JC (1977) Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice. Cancer Treat Rep 61:409
Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER (1975) l-Phenylalanine mustard (l-PAM) in the management of primary breast cancer. N Engl J Med 292:117
Guarino AM, Rozencweig M, Kline I, Penta JS, Venditti JM, Lloyd HH, Holzworth DA, Muggia FM (1979) Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. Cancer Res 39:2204
Harrison SD Jr (to be published) Variable host response to cytotoxic drugs: lethality, lesions, and lessons. In: Fidler IJ, White RJ (eds) Design of models for screening of therapeutic agents for cancer. Van Nostrand Reinhold, New York
Harrison SD Jr, Burdeshaw JA, Crosby RG, Cusic AM, Denine EP (1978a) Hematology and clinical chemistry reference values for C57BL/6xDBA/2F1 mice. Cancer Res 38:2636
Harrison SD Jr, Denine EP, Peckham JC (1978b) Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF1 mice. Cancer Treat Rep 62:533
Harrison SD Jr, Giles HD, Denine EP (1979) Hematologic and histopathologic evaluation of N-(phosphonacetyl)-l-aspartate (PALA) in mice. Cancer Chemother Pharmacol 2:183
Houghton JA, Houghton PJ, Wooten RS (1979) Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39:2406
Luna LG (ed) (1968) Manual of histologic staining methods of the Armed Forces Institute of Pathology, 3rd edn. McGraw-Hill, New York, 32
Lundholm K, Edstrom S, Ekman L, Karlberg I, Bylund A, Schersten T (1978) A comparative study of the influence of malignant tumor on host metabolism in mice and man. Cancer 42:453
Pazdernik TL, Uyeki EM (1978) Cyclophosphamide. I. Effects of survival and colony-forming cells in BDF1 L-1210-bearing mice. J Pharmacol Exp Ther 207:255
Penta JS, Rozencweig M, Guarino AM, Muggia FM (1979) Mouse and large animal toxicology studies of twelve antitumor agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3:97
Perin A, Sessa A (1978) Changes in polyamine levels and protein synthesis rate during rat liver carcinogenesis induced by 4-dimethylaminoazobenzene. Cancer Res 38:1
Prieur DJ, Young DM, Davis RD, Cooney DA, Homan ER, Dixon RL, Guarino AM (1973) Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: Protocols of the Laboratory of Toxicology. Cancer Chemother Rep 4:1
Reed DJ (1976) Effects in vivo of lymphoma ascites tumors and procarbazine, alone and in combination, upon hepatic drug-metabolizing enzymes of mice. Biochem Pharmacol 25:153
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harrison, S.D., Giles, H.D. & Denine, E.P. Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother. Pharmacol. 4, 199–204 (1980). https://doi.org/10.1007/BF00254019
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254019